000727704 000__ 03155cam\a2200445Ii\4500
000727704 001__ 727704
000727704 005__ 20230306140933.0
000727704 006__ m\\\\\o\\d\\\\\\\\
000727704 007__ cr\cn\nnnunnun
000727704 008__ 150616s2015\\\\sz\\\\\\ob\\\\001\0\eng\d
000727704 020__ $$a9783319141510$$qelectronic book
000727704 020__ $$a3319141511$$qelectronic book
000727704 020__ $$z9783319141503
000727704 035__ $$aSP(OCoLC)ocn911054471
000727704 035__ $$aSP(OCoLC)911054471
000727704 040__ $$aN$T$$beng$$erda$$epn$$cN$T$$dN$T$$dIDEBK$$dGW5XE$$dCDX$$dYDXCP$$dEBLCP$$dUPM
000727704 049__ $$aISEA
000727704 050_4 $$aRM666.E548
000727704 08204 $$a615.19$$223
000727704 24500 $$aPARP inhibitors for cancer therapy$$h[electronic resource] /$$cNicola J. Curtin, Ricky A. Sharma, editors.
000727704 264_1 $$aCham :$$bHumana Press :$$bSpringer,$$c[2015]
000727704 264_4 $$c©2015
000727704 300__ $$a1 online resource (xix, 591 pages)
000727704 336__ $$atext$$btxt$$2rdacontent
000727704 337__ $$acomputer$$bc$$2rdamedia
000727704 338__ $$aonline resource$$bcr$$2rdacarrier
000727704 4901_ $$aCancer drug discovery and development ;$$vv. 83
000727704 504__ $$aIncludes bibliographical references and index.
000727704 5050_ $$aHistory of the discovery of poly (ADP-ribose) -- Discovery of the PARP superfamily and focus on the lesser exhibited but not lesser talented members -- The role of PARPs in DNA Strand Break Repair -- TIPs: Tankyrase Interacting Proteins -- PARP and Carcinogenesis -- Multitasking roles for poly(ADP-ribosyl)ation in aging and longevity -- Overview of PARP Inhibitor Design and Optimization -- Structure Based Design of PARP Inhibitors -- Preclinical chemosensitization by PARP inhibitors -- Classification of PARP inhibitors based on PARP trapping and catalytic inhibition, and rationale for combinations with topoisomerase I inhibitors and alkylating agents -- Radiosensitisation by poly(ADP-ribose) polymerase inhibition -- The vasoactivity of PARP inhibitors -- Synthetic lethality with Homologous Recombination Repair defects -- Targeting tumour hypoxia with PARP Inhibitors: Contextual synthetic lethality -- Other determinants of sensitivity -- Synthetic sickness with molecularly targeted agents against the EGFR pathway -- Disruption of DNA repair by cell cycle and transcriptional CDK inhibition -- Resistance to PARP Inhibitors Mediated by Secondary BRCA1/2 Mutations -- PARP inhibitor resistance -- what is beyond BRCA1 or BRCA2 restoration -- Introduction to PARPi clinical trials and future directions -- Clinical trials investigating PARP inhibitors as single agents -- Clinical trials of PARP inhibitors with chemotherapy -- Combination of PARP inhibitors with clinical radiotherapy -- Biomarkers for PARP Inhibitors.
000727704 506__ $$aAccess limited to authorized users.
000727704 650_0 $$aNAD-ADP-ribosyltransferase$$xInhibitors$$xTherapeutic use.
000727704 650_0 $$aEnzyme inhibitors$$xTherapeutic use.
000727704 650_0 $$aCancer$$xTreatment.
000727704 7001_ $$aCurtin, Nicola J.,$$eeditor.
000727704 7001_ $$aSharma, Ricky A.,$$eeditors.
000727704 830_0 $$aCancer drug discovery and development ;$$vv. 83.
000727704 852__ $$bebk
000727704 85640 $$3SpringerLink$$uhttps://univsouthin.idm.oclc.org/login?url=http://link.springer.com/10.1007/978-3-319-14151-0$$zOnline Access$$91397441.1
000727704 909CO $$ooai:library.usi.edu:727704$$pGLOBAL_SET
000727704 980__ $$aEBOOK
000727704 980__ $$aBIB
000727704 982__ $$aEbook
000727704 983__ $$aOnline
000727704 994__ $$a92$$bISE